Teachers Advisors LLC Purchases 8,340 Shares of Loxo Oncology, Inc. (LOXO)

Teachers Advisors LLC raised its holdings in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 29.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,502 shares of the biopharmaceutical company’s stock after purchasing an additional 8,340 shares during the quarter. Teachers Advisors LLC owned approximately 0.14% of Loxo Oncology worth $2,927,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Bank of America Corp DE lifted its holdings in Loxo Oncology by 162.6% during the 1st quarter. Bank of America Corp DE now owns 8,176 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 5,063 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in Loxo Oncology by 41.5% during the 1st quarter. Driehaus Capital Management LLC now owns 598,863 shares of the biopharmaceutical company’s stock valued at $25,200,000 after purchasing an additional 175,587 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Loxo Oncology during the 2nd quarter valued at $5,415,000. Federated Investors Inc. PA lifted its holdings in Loxo Oncology by 21,561.6% during the 2nd quarter. Federated Investors Inc. PA now owns 37,258 shares of the biopharmaceutical company’s stock valued at $2,988,000 after purchasing an additional 37,086 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in Loxo Oncology by 53.5% during the 1st quarter. Swiss National Bank now owns 28,700 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 10,000 shares during the last quarter.

In other Loxo Oncology news, Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $90.00, for a total value of $450,000.00. Following the sale, the director now owns 144,118 shares of the company’s stock, valued at approximately $12,970,620. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Naarden Jacob Van sold 1,541 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $73.73, for a total value of $113,617.93. Following the completion of the sale, the insider now directly owns 1,541 shares in the company, valued at approximately $113,617.93. The disclosure for this sale can be found here. Insiders have sold a total of 89,896 shares of company stock worth $7,315,562 in the last three months. 44.40% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Teachers Advisors LLC Purchases 8,340 Shares of Loxo Oncology, Inc. (LOXO)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/teachers-advisors-llc-has-2-93-million-stake-in-loxo-oncology-inc-loxo.html.

Shares of Loxo Oncology, Inc. (LOXO) opened at 85.81 on Friday. The stock’s 50 day moving average price is $86.70 and its 200-day moving average price is $70.19. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $95.92. The firm’s market cap is $2.56 billion.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.15). During the same period in the prior year, the company posted ($0.77) earnings per share. On average, analysts predict that Loxo Oncology, Inc. will post ($4.39) earnings per share for the current fiscal year.

Several equities research analysts have issued reports on LOXO shares. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price target (up previously from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. Ifs Securities reaffirmed an “outperform” rating on shares of Loxo Oncology in a report on Tuesday, August 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $71.00 price target on shares of Loxo Oncology in a report on Thursday, August 3rd. BTIG Research reissued a “buy” rating and set a $102.00 target price (up previously from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Finally, Citigroup Inc. reissued a “buy” rating and set a $112.00 target price (up previously from $86.00) on shares of Loxo Oncology in a report on Friday, October 20th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $80.02.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply